Published July 11, 2022 | Version v.1
Journal article Open

Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer

  • 1. Department of Clinical Pharmacology, National Institute of Oncology, Chest and Abdominal Tumours Chemotherapy "B", Budapest, Hungary.
  • 2. Center of Oncoradiology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.
  • 3. Department of Oncology, Szent Margit Hospital, Budapest, Hungary
  • 4. Clinic Center of Excellence, Heart and Brain Hospital, Science and Research Institute, Medical University-Pleven, Pleven, Bulgaria
  • 5. Oncology Centre, Semmelweis University, Budapest, Hungary.
  • 6. Oncotherapy Clinic, University of Szeged, Szeged, Hungary.
  • 7. Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan.
  • 8. Institute of Oncotherapy, Faculty of Medicine, University of Pécs, Pécs, Hungary
  • 9. 1st Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.; Medical Oncology Department, St. Elisabeth Cancer Institute, Bratislava, Slovakia.
  • 10. Department of Oncology, Szent Rafael Hospital of Zala County, Zalaegerszeg, Hungary.
  • 11. County Oncology Centre, Pándy Kálmán Hospital of Békés County Council, Gyula, Hungary.
  • 12. Institute for Oncology and Radiology of Serbia, Daily Chemotherapy Hospital, Belgrade, Serbia

Description

This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Breast Cancer, modified based on the international consultation and conference within the frames of the Central-Eastern European Academy of Oncology. The professional guideline primarily reflects the resolutions and recommendations of the current ESMO, NCCN and ABC5, as well as that of the St. Gallen Consensus Conference statements. The recommendations cover classical prognostic factors and certain multigene tests, which play an important role in therapeutic decision-making. From a didactic point of view, the text first addresses early and then locally advanced breast cancer, followed by locoregionally recurrent and metastatic breast cancer. Within these, we discuss each group according to the available therapeutic options. At the end of the recommendations, we summarize the criteria for treatment in certain rare clinical situations.

Notes

FUNDING The publication fee is covered by funding of the Central Eastern European Academy of Oncology Foundation, National Institute of Oncology 1122 Budapest Ráth Gy. u 7-9. This corrects the article "Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer" in volume 28, 1610383. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927865/

Files

Systemic Treatment of Breast Cancer..pore-28-1610383.pdf

Files (1.1 MB)

Additional details